ACADEMIA
Tolvaptan Reduces Body Weight, Improves Congestive Symptoms; Adverse Reactions Seen in Less than 20% of Patients: Interim Analysis of PMS Data
An interim analysis of post-marketing surveillance of the vasopressin V2-receptor antagonist tolvaptan (brand name: Samsca) was announced at the 78th Annual Scientific Meeting of the Japanese Circulation Society on March 22. Tolvaptan significantly reduced body weight and improved congestive symptoms…
To read the full story
ACADEMIA
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





